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ACTG1
actin-1 (mRNAs). At least 70% of miRNAs are expressed in the central nervous system (CNS), and during development, they are heterochronic molecules that are conserved among species (Lagos-Quintana et al., 2002; McNeill and Van Vactor, 2012) .
During CNS development, several miRNAs present specific expression patterns and are important regulators of this process, controlling neural stem cell (NSC) and progenitor proliferation, migration, and differentiation by inhibiting the translation of multiple mRNA targets and/or the action of several miRNAs on the same mRNA target (Bernstein et al., 2003; Chi et al., 2009; Krichevsky et al., 2006; Nielsen et al., 2009 ). The role of miRNAs during neural development has been corroborated by the loss-of-function of Dicer or Drosha (or its cofactor DGSR8), which are key components of miRNA biogenesis (Davis et al., 2008; Giraldez et al., 2005; Kanellopoulou et al., 2005; Wang et al., 2007) .
During neurogenesis and neural tube (NT) development in rats and mice and in in vitro models of human CNS development, are upregulated (Ji et al., 2013; Krichevsky et al., 2006; Nielsen et al., 2009; Stappert et al., 2015) . , and -9 promote neuronal differentiation Lattanzi et al., 2013; Maiorano and Mallamaci, 2009, 2010; Silber et al., 2008; Smrt et al., 2010) . In contrast, miR-183 and the miR-8/-200 family have been classified as anti-apoptotic, neural progenitor maintenance, and proliferative molecules (Genini et al., 2014; Morante et al., 2013; Peng et al., 2012) .
Gestational diabetes mellitus (GDM) is known to affect the development of the fetal nervous system, which is associated with inadequate fetal programming, leading to changes in the ontogeny of systems with short-and long-term negative consequences for the structure and function of organs and tissues (Mitanchez et al., 2015) . Liao and collaborators showed in mice that diabetes during pregnancy promotes forebrain hyperplasia by increasing the expression and altering the pattern of fetal inductive signaling molecules, such as sonic hedgehog (Shh) and brain factor-1 (Liao et al., 2004) . Interestingly, the increase in Shh is related to the expression of homeobox transcription factor Nkx2.1 in the diencephalon, which is required for the formation of the ventral forebrain (Sussel et al., 1999) . In embryos from diabetic mice, the expression of Nkx2.1 is also increased and is expanded toward the telencephalon (Liao et al., 2004) , suggesting changes in the ventral-dorsal patterning of the NT. Fu and collaborators reported changes in the proliferation and differentiation of NSCs associated with changes in the expression of genes involved in cell-cycle progression and cell-fate specification, such as Shh, bone morphogenetic protein 4, neurogenin 1/2, Achaetescute homolog 1 (Ascl1), Hes family BHLH transcription factor 1 (Hes1), Delta-like protein 1 (Dll1), and oligodendrocyte transcription factor 1 (Olig1), in a high-glucose environment (Fu et al., 2006) . Stecolourum and Boutet (2011) also demonstrated changes in the postnatal hypothalamic cytoarchitecture and function in offspring from diabetic mice, which resulted in central leptin resistance, increased food consumption, and postnatal obesity (Steculorum and Bouret, 2011) . Interestingly, high incidences of obesity, low intellectual and verbal coefficients, impaired language and motor skills, attention deficit hyperactivity disorder, and psychosocial developmental problems have been reported in children from mothers with GDM (Camprubi Robles et al., 2015; Ornoy, 2011; Ornoy et al., 2001; Ornoy et al., 1999; Stenninger et al., 1998) .
Interestingly, higher levels of miRNAs have been associated with NT defects (NTDs) and fetal growth restriction (Gu et al., 2012; Mouillet et al., 2010) . However, fetal CNS development-related molecules have never been investigated by measuring the serum miRNA levels at different times during healthy pregnancy and comparing the results with those measured during GDM. Doing so will contribute to the use of miRNAs as potential biomarkers.
The aim of this study was to analyze whether the heterochronic character of developmentrelated miRNAs can be observed in serum samples from pregnant women and to compare their levels in each trimester with samples collected from gestational diabetics, as hyperglycemia is known to increase neurogenesis. Thus, we carefully selected 12 neural development-related miRNAs based on reported evidence of their mRNA targets, expression profiles, and functions during CNS development in vivo or in vitro (Table 1) .
Aquantitative reverse-transcriptase polymerase chain reaction (qRT-PCR) approach was used to evaluate the changes in these miRNAs' levels during pregnancy and between control and GDM groups. After identifying the miRNAs that increased significantly, an in silico analysis was performed to highlight the related biological pathways and processes.
Materials and Methods
All procedures were performed in accordance with the Helsinki Declaration and accepted by the Research and Ethics Committee of the Instituto Nacional de Perinatología (protocol number 2122250-21121). All participants signed an informed consent that included the authorization of each participant for miRNA sample analysis and the publication of data. The consent letter was approved by the internal ethics committee.
Sample collection and groups
Women between 18 and 35 years old with no antecedents of diabetes, a body mass index below 29, and no other metabolic or infectious disease at the time of sampling were included.
The participants were assigned to one of the following groups: nulliparous (Np; nonpregnanthealthy women with no prior pregnancies or abortions, used as negative controls, control pregnant women (with no metabolic diseases), and GDM women (diagnosed according to the two-step protocol recommended by theAmerican Diabetes Association ([ADA] ; American Diabetes, 2017). Participants should not have had a diagnosed NTD, and samples were collected before nutritional and/or pharmacological treatment to eliminate the possible effect of treatment on the miRNAs levels.
The number of samples included in the analysis of miR-125b-5p were as follows: 74 samples from the control group (27, 26, and 21 collected during the first, second, and third trimesters, respectively), 67 samples from the GDM group (14, 26, and 27 collected during the first, second, and third trimesters, respectively) and 10 samples from the Np group. For the twelve fetal neural-related miRNAs array analysis, the number of samples analyzed were as follows:
54 samples in the control group (12, 24, and 16 from the first, second, and third trimesters, respectively), 57 samples in the GDM group (13, 24, and 20 from the first, second, and third trimesters, respectively), and 10 samples from the Np group. The number of samples was reduced for the array qPCR relative to the number used in the miR-125b-5p analysis because some samples showed amplification cycle thresholds exceeding 29, suggesting non-specific amplification (Livak and Schmittgen, 2001 ).
The ADA suggests that pregnant women who test positive for diabetes during the first trimester of pregnancy must not be considered as GDM but as type 2 diabetics. Nevertheless, in this study, we classify all women as GDM because no risk factors for type 2 diabetes, such as obesity, first-degree family history of diabetes, and history of abnormal glucose metabolism, were reported by the women.
As part of an institutional program for the early detection of diabetes during pregnancy, all women admitted to the "Instituto Nacional de Perinatología" are, regardless of their gestational age, screened for diabetes, as described in the ADA's two-step approach. To this end, we performed a first glucose tolerance curve with 50 g of glucose, and if the plasma glucose level after 1 hour was ≥130 mg/dl, a second curve with 100 g of glucose was performed within the next 2 weeks. If the fasting glucose value was ≥95 mg/dl, and an abnormal glucose tolerance curve was observed, the diagnosis of GDM was positive.
Five milliliters of peripheral blood were obtained by venipuncture in vacutainer tubes without anticoagulant agents and centrifuged at 470×g for 10 min to obtain the serum fraction. Serum fraction aliquots (500 l) were made in sterile, nuclease-and pyrogen-free, 1.5-ml vials and stored at -70 °C until use. Hemolytic samples were discarded.
RNA extraction
Before RNA extraction, 1.6×10 8 copies of synthetic Cel-miR-39-3p were added to each sample as a normalizer for the qPCR analysis. Total RNA was obtained using TRIzol reagent The RNA purity was determined based on the relationship between the absorbances determined at 260 and 280 nm (Abs260/Abs280). Samples with values between 1.8 and 2
were included.
Finally, the presence of miRNAs in the total RNA extracts was corroborated using the small RNA kit chip protocol (http://www.chem.agilent.com/library/usermanuals/Public/G2938-90093_SmallRNA_KG_EN.pdf), a 2100 Bioanalyzer, and "2100 expert" software (Agilent Technologies, Santa Clara, CA, USA).
Reverse transcription of miRNAs
As a first approach, miR-125b-5p was selectively amplified because of its relevance in forebrain-hindbrain boundary formation and neuron differentiation (Lattanzi et al., 2013; Le et al., 2009b Le et al., , 2010 . MiR-125b-5p was reverse transcribed from 0.5 l of total RNA in a 
qPCR
The qPCR conditions for miR-125b-5p were as follows: pre-amplifications were performed with a mixture of 1 lofcDNA, 10 pmol of the universal primer (sequence: 5'-GTG CAG GGT CCG AGG T-3'), 10 pmol of the specific primer (sequence: for miR-125b-5p, 5'-CGG CCG TCC CTG AGA-3', and for Cel-miR-39-3p, 5'-CGC CCG TGA CCG GGT G-3'; IDT), 10 mM of each dNTP, and 5 U of Taq polymerase (GoTaq Flexi, Promega). The preamplification protocol was as follows: 95 °C for 10 minutes followed by 12 cycles at 95 °C for 10 s, 58 °C for 10 s, and 74 °C for 10 s. One microliter of the pre-amplification reaction mixture was combined with 10 pmol of the universal primer, 10 pmol of the specific primer, and PCR Master Mix 2X KAPA TM SYBER FAST qPCR (KapaBiosystems, Wilmington, Mass, USA). The mixture was denatured at 95 °C for 10 minutes, followed by 40 cycles at 95 °C for 10 s, 58 °C for 10 s, and 74 °C for 10 s in a Rotor-Gene 6000 (Qiagen).
Amplifications were performed in triplicate for each sample.
The fluorescence threshold was set at 0.2 for both miRNAs; this value was determined based on the dynamic ranges of the amplification curves (not shown). 
Sequencing
The PCR products corresponding to miR-125b-5p and Cel-miR-39-3p were visualized in 4%
agarose gel by electrophoresis. The bands were isolated and purified using the Zymoclean™ Gel DNA Recovery Kit (Zymo Research, CA, USA), and the cDNA was sent to the Unidad de Proteogenomica at the Instituto de Neurobiología-UNAM for cloning and sequencing with a BigDye termination sequencing kit (Applied Biosystems, Carlsbad, CA, USA) using a thermocycler and sequencer ABI PRISM 310 Genetic Analyzer (Applied Biosystems).
Cloning sequences were compared with the corresponding mature miRNA sequences in the miRBase data bank (http://www.mirbase.org/; Manchester, UK).
Relative expression analysis
As mentioned above, samples with threshold cycles exceeding 29 were excluded from the analysis because they were considered to represent non-specific amplification. When no cycle was obtained at the threshold fluorescence, samples were considered as "not-detected
The temporal analysis of the control group and the differences between groups was performed using the 2 -CT method forrelative expression (Livak and Schmittgen, 2001) using Cel-miR-39-3p as a normalizer. For the temporal analysis of the control group, the results are expressed relative to the first trimester, whereas for between-groups comparisons, the results are presented relative to the control group values.
In silico analysis
The in silico analysis was performed when at least two miRNAs increased significantly. The graphs do not include biological pathways or processes related to oncogenic or infectious events.
DIANA V.3 mirPath (Vlachos et al., 2012; Vlachos et al., 2015) and a database containing experimentally corroborated miRNAs' mRNA targets in the 3' untranslated regions (3'UTRs, Tarbase v7.0) were used to perform a Kyoto Encyclopedia of Genes and Genomes (KEGG)
analysis and Gene Ontology (GO) biological process analysis with a threshold value of p<0.05. The KEGG analysis results are expressed as the -ln of the p value (-ln(p value)).
The chart obtained from the GO analysis of the diabetic group was modified from that obtained from the EBIDatabasesQuickGO website (http://www.ebi.ac.uk/QuickGO/).
Statistics
Graphs and statistical analyses were performed using GraphPad Prism 6 software (GraphPad Software, Inc., La Jolla, CA, USA). To assess the temporal changes a two-way analysis of variance (ANOVA) was performed, followed by Tukey's multiple comparison test, whereas for differences between groups, an unpaired t-test was used.
Results

Temporal changes in the miR-125b-5p level in control pregnant women and between groups per trimester
The relative expression of miR-125b-5p during pregnancy showed temporal changes in the control group in accordance with fetal neurogenesis, as expected (Bystron et al., 2008;  2.6-fold increases in the relative expression level of miR-125b-5p during the second and third trimesters, respectively ( Figure 1A ).
In the GDM group, we observed that the relative expression level of the miRNA was significantly increased (1.7-fold) in the first trimester and decreased (10-fold) in the second trimester relative to those in the control group ( Figure 1B ). Finally, in the Np samples, we found 3.2-fold lower expression relative to the control group ( Figure 1B ).
We also confirmed that the PCR product (75 bp) isolated from the 4% agarose gels was consistent with the sequences reported for the mature human miR-125b-5p (accession number MIMAT0000423) and the mature Cel-miR-39-3p (accession number MIMAT0000010) in the miRBase (data not shown).
Fetal-related miRNAs levels in control pregnant women and between groups per trimester
Using a customized RT-qPCR array, we found temporal changes in the relative expression levels of four miRNAs in serum of control pregnant women. During the second trimester, miR-183-5p, -200b-3p, and -125b-5p were highly expressed, whereas the highest level of miR-137 was observed in the third trimester ( Figure 2 ).
As expected, the expression of the miRNAs ranged from nd to no changes in the Np samples relative to the control group. Non-detected miRNAs were miR-183-5p, -137, -191-5p and -1290, whereas the levels of miR-200b-3p, 17-5p, -125b-5p, and -128-5p were very low in Np samples. Finally, miR-9-5p, -30b-5p, -30c-5p, and -124a-3p showed no changes relative to the control group at all trimesters (Figures 3A).
In contrast, during the first trimester, the relative expression levels of miR-183-5p, -200b-3p, -125b-5p, and -1290 were higher in the GDM group ( Figure 3A ). During the second trimester, in the GDM group, the expression levels of miR-183-5p and miR-128-5p were higher and lower, respectively, compared with the control group ( Figure 3B ). Finally, during the third trimester, in the GDM group, we observed a higher level of miR-137 and lower levels of miR-183-5p and -200b-3p relative to the control group ( Figure 3C ).
In silico analysis
The in silico analysis included miR-183-5p, -200b-3p, and -125-5p, which were overexpressed during the second trimester in the control group. The KEGG analysis revealed 21 related pathways ( Figure 4A ). The three pathways with the highest scores were the adherens junction pathway (hsa04520), hippo signaling (hsa04390), and actin cytoskeleton regulation (hsa04810); these pathways' -ln(p-value) values were 24.5, 17.1, and 12.3, respectively ( Figure 4A ). Interestingly, the experimental mRNA targets that participated in these three pathways were actin- (ACTB) and actin-1 (ACTG1). These genes are also involved in thyroid hormone and focal adhesion pathways (Table 2 ).
Other targets of miR-183-5p, -200b-3p, and -125-5p include tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein gamma (YWHAG; Hippo) and protein phosphatase 2 catalytic subunit alpha (PPP2CA; Hippo), which are involved in the cell cycle (hsa04110) and transforming growth factor  (TGF-hsa04350) pathways, respectively, and CRK-like proto-oncogene, adaptor protein (CRKL; actin cytoskeleton regulation), which is involved in the tyrosine kinase receptor pathway of the epidermal growth factor-related receptor protein family (EbrB; hsa04012) and focal adhesion (hsa04510) and neurotrophin (hsa04722) pathways (Table 2) .
We also performed an in silico analysis of miR-183-5p, -200b-3p, -125-5p, and -1290 because these presented the highest levels during the first trimester in the GDM group. The three pathways with the highest scores were the adherent junction (-ln(p value) = 28.3), hippo signaling (-ln(p value) = 15.8), and p53 (hsa04115; -ln(p value) = 11.3) ( Figure 4B and Table 2 ). The miR-1290 targets of these pathways are also involved in the Wnt signaling (casein kinase 2 alpha 2 (CSNK2A2)), Ras-proximate-1 or Ras-related protein 1 (Rap1;
catenin delta 1 (CTNND1)), cell cycle (YWHAQ, cyclin G2 (CCNG2), MDM2 protooncogene (MDM2)), TGF- (bone morphogenetic protein receptor type 2 (BMPR2)), and forkheadBoX (FoxO; CCNG2 and MDM2) pathways (Table 2 ).
The GO biological process analysis of the GDM group revealed that the four analyzed miRNAs participate in cellular protein modification processes (GO:0006464) at similar levels ( Figure 5A ). Actin modification (GO:0030047) is a cellular protein modification process that includes the regulation of neuron remodeling (GO:1904799; Figure 5B ).
Discussion
Because of the heterochronic nature of miRNAs during development, establishing specific time windows during fetal development is important to explain specific biological processes.
Nevertheless, the precise moments at which cell proliferation, migration, and neuron differentiation occur during human embryonic development are unknown. However, several studies suggest that the NT closes at day 28 (first trimester; Crider et al., 2014; Nakatsu et al., 2000) , when the telencephalicprimordium consists mostly of proliferating cells (NSCs)
that divide symmetrically to increase the surface and thickness of the neuroepithelium in the ventricular zone. Asymmetrical cell division marks the beginning of neurogenesis at day 33 (first trimester), whereas cerebral cortex neurogenesis initiates at week 10 (first trimester) and reaches its highest level at week 16 (second trimester). Finally, the characteristic sixlayer pattern within the cerebral cortex can be distinguished until week 28 of gestation (third trimester; Bystron et al., 2008; Bystron et al., 2006; Carney et al., 2007) .
MiRNAs have been proposed as biomarkers for several physiological and pathological conditions because their levels in tissues correlate with those in various body fluids and because miRNAs are quite stable against heat, pH, and repetitive thawing (Cortez et al., 2011; Cortez and Calin, 2009; Chen et al., 2014; Chen et al., 2008; Gilad et al., 2008; Kroh et al., 2010) . However, the serum levels of fetal-miRNAs do not necessarily reflect those in fetal tissue, and the only way to confirm this relationship would be to obtain experimental data from both the pregnant woman and the fetus binomial simultaneously; this type of study is prohibited in humans because of ethical issues.
Therefore, in this study we divided sample groups into trimesters and evaluated the fetal neural development-related miRNA expression levels in maternal serum during the time frames expected to correspond to the proliferative, neurogenic and neuron maturation processes in human development based on the expression patterns of the selected miRNAs during these processes in animal and human models of CNS development.
Several studies have revealed that miRNAs are differentially expressed during murine CNS development and during the cell proliferation and neural differentiation of human and mouse cell lines (e.g., PC12, embryonic cells, and NSCs) Diaz et al., 2014) . Gu and collaborators (2012) performed a microarray study followed by qRT-PCR validation and identified six fetal miRNAs linked to NTDs in the serum of pregnant women. Mouillet and collaborators (2010) evaluated hypoxia-related miRNAs in the serum of control pregnant women and those with fetal growth restriction and found gestational age-dependent changes by qRT-PCR. These two studies differ in terms of the possible use of serum miRNAs as biomarkers, with the first recommending the use of these molecules to evaluate NTDs and the second concluding that the use of serum miRNAs as biomarkers for placental dysfunction is not recommended.
Here, we agree with Gu and collaborators, suggesting that miRNAs involved in the development of the CNS could be future biomarkers, most importantly during fetal development, where no evidence can be obtained through current diagnostic techniques (e.g., ultrasonic imaging systems). However, more research is necessary to establish these molecules as biomarkers of fetal development. In particular, miR-125b-5p is part of a group of miRNAs that act as switches from the multipotent stage to neuron differentiation by repressing multiple and differential mRNA targets and is a master controller of the p53 pathway, which is involved in the regulation of apoptosis in several species, including humans (Le et al., 2011; Le et al., 2009a; Le et al., 2009b) . In the zebrafish model, the loss or gain of the function of this miRNA at the two-cell embryo stage promotes the shrinking of the head because of excessive cell death in the brain and a curvature of the body axis (somite defects). In contrast, the knockdown or ectopic expression of this miRNA promotes the loss of the midbrain-hindbrain boundary, which is the most important organizer of the brain (Le et al., 2010) . The expression of miR-125b has also been reported to increase during neurogenesis (Krichevsky et al., 2006; Nielsen et al., 2009) and to promote neuron differentiation by suppressing the neuronal-inhibitory effect of the Notch signaling pathway (Le et al., 2010) .
As expected, our results showed that miR-125b-5p, a neurogenic miRNA, increased during the second trimester in the control group and during the first trimester in the GDM group relative to the control group. This finding suggests that tissue level changes can be reflected in the serum of pregnant women, a hypothesis supported by the very low level of this miRNA in the Np group. However, miR-125b-5p is also expressed in the placenta, where a higher level was reported in the third trimester compared with the first trimester (Gu et al., 2013) .
Additionally, in the context of placental pathologies, such as intrauterine growth restriction, hypertension, or preeclampsia, this miRNA has been reported in placentas and serum samples collected before week 34 (Hromadnikova et al., 2015 (Hromadnikova et al., , 2016 . Nonetheless, those authors reported low expression levels of miR-125b-5p, in contrast with our results.
Our findings also suggest that not all miRNAs are feasible as biomarkers for fetal CNS development and that only miRNAs that are absent or expressed at very low levels in the Np group can be considered. This conclusion was also supported by the fact that in the control, miR-183-5p and miR-200b-3p (considered to be proliferative miRNAs) and miR-125b-5p (a neurogenic miRNA) increased significantly only during the second trimester, and that miR- Finally, the GO biological process analysis suggested that the increased miRNAs in the GDM group participate in nervous system development by blocking the negative regulation of neurogenesis, which could in turn be related to increased neuron differentiation early during fetal development, similar to the murine model (Fu et al. 2006 ).
Conclusion
Our results suggest that fetal related neural development miRNAs can be detected in the serum of pregnant women; that some of these miRNAs exhibit a temporal regulation that might be related to fetal CNS development, and that specific miRNAs are overexpressed in the GDM group, which may be related to alterations in cell proliferation and neurogenesis during the first trimester of pregnancy. Tables. HSPA1A, CBL, VTA1, PIP5K1C, CAV1, IGF1R, ARF1, GBF1, CHMP2B, ARFGAP2, VPS37A, USP8, RAB22A, SMAD7, HSPA1B, RAB5B, SMAD2, CBL, ARF3, SMURF2, NEDD4L, RAB7A, EEA1, ITCH, SH3GL1, PLD1, RHOA, ASAP1, CHMP2B, FLT1, HSPA8, RAB22A, ARF6, KDR, PARD6B, and RAB5B. HSPA1A, ARF3, PIP5K1C, VPS36, ARF1, CLTC, ARFGEF2, ERBB3, VPS37B, RAB1, 1FIP2, EPS15, TFRC, RAB11A, USP8, CHMP3, VPS37C, ARF6, LDLR, SMAD7, FGFR2, HSPA1B, EHD1, and PARD6B. ADRBK2, CLTC, CYTH4, CYTH1, and FBXO32, CCNB1, NRAS, STK4, PCK2, IGF1R, KRAS, CCND1, SMAD4, IRS4, SOD2, PTEN, SGK3, FOXO1, MAPK1, and BCL2L11. SMAD2, BNIP3, SIRT1, SETD7, CDK2, CDKN1B, KRAS, NLK, CCND1, SKP2, PLK2, EP300, ATG12, and BCL2L11. NRAS, MAPK14, STK11, RAF1, CDKN1B, CDKN2B, AKT1, IRS4, PRKAG1, GABARAPL1, INSR, SOD2, CDKN1A, and NRAS, ROCK2, ROBO2, KRAS, PAK1, SLIT2, RAC1, PLXNB1, NTN4, EPHA4, NFATC3, MAPK1, and EFNA1. PAK2, SRGAP1, RHOA, KRAS, PPP3CA, PTK2, DCC, CFL2, LIMK1, and EFNA1. EFNB2, NRAS, PAK2, ARHGEF12, EPHA7, PLXNB3, NRP1, SEMA4C, SEMA4B, EPHA4, NFATC3, STK4, IGF1R, GNB1, KRAS, PAK1, PTPN11, RAC1, FGF2, PDGFC, RALGDS, MAPK1, ABL2, GNG5, RAB5B, EFNA1, and RASSF5. KSR1, RASA2, SHC1, PAK2, ETS1, RALBP1, PLD1, RHOA, KRAS, PLCG1, REL, FLT1, TBK1, GAB1, ARF6, RGL1, VEGFA, FGFR1, ABL2, KDR, RAP1B, RAB5B, miR-125-5p miR-1290 PFN1, BRAF, ACTB, ITGB1, NRAS, CRKL, IGF1R, KRAS, CDH1, PFN2, RAPGEF2, RAC1, FGF2, PDGFC, VASP, RALGDS, MAPK1, PLCB4, EFNA1, and RASSF5. CRKL, CRK, RHOA, KRAS, PLCG1, FLT1, VEGFA, FGFR1, KDR, ADCY9, PARD6B, RAP1B, and EFNA1. PRKCA, SIPA1L3, NRAS, CRKL, CRK, THBS1, MAPK14, ACTG1, RAF1, TIAM1, MLLT4, CTNNB1, RAPGEF2, AKT1, INSR, PDGFD, FGFR2, VEGFA, FGFR1, PARD6B, and RASSF5. C, KRAS, CALM2, AKT2, and 
FADS1.
*Gray: highest enrichment score pathways in control and GDM.
